Written answers
Wednesday, 11 May 2022
Department of Health
Medicinal Products
Denis Naughten (Roscommon-Galway, Independent)
Link to this: Individually | In context | Oireachtas source
258. To ask the Minister for Health when the HSE will approve the reimbursement under the high-tech drug arrangements for kaftrio for children under 12 years of age; the reason for the delay in approval in view of the fact that it has already been approved for children aged 12 years and over; the date when the applicant company submitted a rapid review dossier of evidence to the HSE; the steps taken by the HSE to consider this dossier; the dates on which these steps were taken; if all outstanding queries have been addressed by the applicant company; if so, when; and if he will make a statement on the matter. [23711/22]
Stephen Donnelly (Wicklow, Fianna Fail)
Link to this: Individually | In context | Oireachtas source
Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for the administration of the community drug schemes; therefore, the matter has been referred to the HSE for attention and direct reply to the Deputy.
No comments